Clinical Equivalence of Budesonide HFA MDI Versus Budesonide Turbuhaler in Mild to Moderate Chinese Asthma Patients

Inclusion Criteria: * Aged 18 to 70 years old and diagnosed as Asthma in clinics * Diagnosed as Asthma according to the 2016 Asthma guidance of Chinese Thoracic Society, and without administer corticosteroids within three months, either new or old patients * FEV1 predicted ≧ 60% * Patients is willing to participate the study and signed the Informed Consent Form Exclusion Criteria: * Allergy to budesonide or salbutamol * Infections of Respiratory tract, nasal-sinus and ear within 4 weeks before enrollment * Severe nasal allergy and need the treatment of corticostreoids and histamines. * Severe cardiovascular disease history * Has used leukotriene receptor antagonist (Montelukast, Pranlukast, Zafirlukast etc.) within 2 weeks before enrollment * Severe cognition or mental disorder and can not cooperation with the treatment * Significant liver dysfunction, AST, ALT \> 3 X normal upper limits, CR \> 1.5 X normal upper limits * Patients with uncontrolled diabetes or fasting blood glucose \> 10 mmol/L * Patients currently receiving beta-antagonists or beta-agonists treatment (including eye drops) * Patients who has contraindications to beta2-agonists * Patients who has participated others drug's clinical study within three months * Female patients who are pregnant or lactation or prepare to pregnant * Any conditions which the investigators considered not suitable to enrolled